A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

@article{Salloway2009AP2,
  title={A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.},
  author={Stephen P. Salloway and Reisa Sperling and Sid Gilman and Nick C. Fox and K Blennow and Murray A. Raskind and Marwan H Sabbagh and Lawrence S. Honig and Rachelle Doody and Christopher H. van Dyck and Ruth A. Mulnard and Jerome Barakos and Keith M. Gregg and Enchi Liu and Ivan Lieberburg and Dale Schenk and Ronald A Black and Michael Grundman},
  journal={Neurology},
  year={2009},
  volume={73 24},
  pages={2061-70}
}
BACKGROUND Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD. METHODS The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). Patients received 6 infusions, 13 weeks apart, with final assessments at week 78. The prespecified primary efficacy analysis… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
35 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

Similar Papers

Loading similar papers…